Replimune Group (NASDAQ:REPL) Lowered to “Sell” at ValuEngine

Replimune Group (NASDAQ:REPL) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, ValuEngine reports.

REPL has been the topic of several other research reports. Chardan Capital set a $28.00 price objective on Replimune Group and gave the company a “buy” rating in a research note on Tuesday, October 15th. Zacks Investment Research cut Replimune Group from a “buy” rating to a “hold” rating in a research report on Thursday. Roth Capital assumed coverage on Replimune Group in a research report on Wednesday, September 4th. They set a “buy” rating and a $20.00 price target on the stock. JPMorgan Chase & Co. upgraded Replimune Group from a “neutral” rating to an “overweight” rating and dropped their price target for the stock from $27.00 to $26.00 in a research report on Friday, July 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Replimune Group in a research report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Replimune Group has an average rating of “Buy” and an average price target of $23.00.

NASDAQ REPL traded up $0.75 on Monday, hitting $14.76. 50,300 shares of the stock traded hands, compared to its average volume of 54,112. The stock has a 50-day moving average of $12.83 and a 200 day moving average of $13.33. Replimune Group has a twelve month low of $8.88 and a twelve month high of $18.25. The company has a market capitalization of $457.58 million, a P/E ratio of -11.10 and a beta of 3.23.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. Research analysts expect that Replimune Group will post -1.52 earnings per share for the current year.

In other news, CEO Robert Coffin sold 24,250 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $17.05, for a total transaction of $413,462.50. Also, COO Colin Love sold 11,250 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $17.05, for a total value of $191,812.50. Insiders have sold a total of 50,000 shares of company stock worth $852,500 over the last quarter. Insiders own 63.18% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC grew its holdings in Replimune Group by 5.7% in the 2nd quarter. Citadel Advisors LLC now owns 186,281 shares of the company’s stock worth $2,731,000 after buying an additional 10,009 shares in the last quarter. Morgan Stanley grew its holdings in Replimune Group by 793.0% in the 2nd quarter. Morgan Stanley now owns 20,709 shares of the company’s stock worth $304,000 after buying an additional 18,390 shares in the last quarter. Vanguard Group Inc. grew its holdings in Replimune Group by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock worth $7,866,000 after buying an additional 36,547 shares in the last quarter. BlackRock Inc. grew its holdings in Replimune Group by 8.2% in the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after buying an additional 76,540 shares in the last quarter. Finally, Foresite Capital Management III LLC grew its holdings in Replimune Group by 4.0% in the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock worth $11,430,000 after buying an additional 30,002 shares in the last quarter. 60.74% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Read More: What is the market perform rating?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.